Distinction of idiopathic Parkinson's disease from multiple-system atrophy by stimulation of growth-hormone release with clonidine (Q67208861)

10 September 2019

issue

9069

1 reference

10 September 2019

page(s)

1877-1881

1 reference

Some specific clinical features differentiate multiple system atrophy (striatonigral variety) from Parkinson's disease

10 September 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2910168-9

7 January 2021

Consensus statement on the definition of orthostatic hypotension, pure autonomic failure and multiple system atrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2910168-9

7 January 2021

Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2910168-9

7 January 2021

The value of urethral sphincter electromyography in the differential diagnosis of parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2910168-9

7 January 2021

Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2910168-9

7 January 2021

Computed tomography, magnetic resonance imaging and positron emission tomography with [18F] fluorodeoxyglucose in multiple system atrophy and pure autonomic failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2910168-9

7 January 2021

Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2910168-9

7 January 2021

Growth hormone response to clonidine in central and peripheral primary autonomic failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2910168-9

7 January 2021

Parkinsonism: onset, progression, and mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2910168-9

7 January 2021

Measurement of growth hormone-releasing factor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2910168-9

7 January 2021

Sites at which Clonidine Acts to Affect Blood Pressure and the Secretion of Renin, Growth Hormone and ACTH

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2910168-9

7 January 2021

Adrenergic control of the secretion of anterior pituitary hormones

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2910168-9

7 January 2021

Plasma DOPA levels and growth hormone response to levodopa in parkinsomism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2910168-9

7 January 2021

L-dopa stimulates release of hypothalamic growth hormone-releasing hormone in humans.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2910168-9

7 January 2021

Stimulation by food of peripheral plasma immunoreactive growth hormone releasing factor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2910168-9

7 January 2021

Inhibition by somatostatin on the release of TSH induced in man by thyrotropin-releasing factor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2910168-9

7 January 2021

Somatostatin and regulation of prolactin secretion.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2910168-9

7 January 2021

Neural control of somatotropic function

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2910168-9

7 January 2021

The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2896%2910168-9

7 January 2021